What is it about?
This is a retrospective study of 15 difficult-to-treat (previous failure, side effects, or resistance to ciprofloxacin and cotrimoxazole) chronic bacterial prostatitis patients (5 with multi-drug resistant Enterobacteriaceae [MDRE]) receiving fosfomycin-tromethamine 3g every 48-72h for 6 weeks. After a median follow-up of 20 months, 7 (47%) had clinical response and 8 (53%) persistent microbiological eradication; 4/5 patients with MDRE isolates achieved eradication. There were no side effects with this prolonged therapy.
Featured Image
Why is it important?
This is the first case series of chronic bacterial prostatitis treated with fosfomycin-tromethamine. Due to increase in resistance to firs line drugs (fluoroquinolones and cotrimoxazole) it may be a possible alternative therapy in this group of patients.
Perspectives
Oral fosfomycin is cost-effective and well tolerated drug. It is a possible alternative therapy in patients with chronic bacterial prostatitis. Further studies are needed to establish the optimal dose and duration of oral fosfomycin in this disease.
Mr Ibai Los-Arcos
Vall d'Hebron Hospital
Read the Original
This page is a summary of: Long-Term Fosfomycin-Tromethamine Oral Therapy for Difficult-To-Treat Chronic Bacterial Prostatitis, Antimicrobial Agents and Chemotherapy, December 2015, ASM Journals,
DOI: 10.1128/aac.02611-15.
You can read the full text:
Contributors
The following have contributed to this page
